文献速递类风湿关节炎

类风湿关节炎生物制剂治疗患者严重感染:英国风湿病学会类风湿关节炎生物制剂登记研究结果

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
PubMed 文献 · Ann Rheum Dis · 2018-03-28

该前瞻性观察队列研究纳入19282例新启用生物制剂的类风湿关节炎患者,随访46771患者年,严重感染发生率为每100患者年5.51例(95%CI 5.29至5.71);与依那西普相比,托珠单抗严重感染风险更高(HR 1.22,95%CI 1.02至1.47),培塞利珠单抗风险更低(HR 0.75,95%CI 0.58至0.97),但该差异在多项敏感性分析中不再显著,提示可能存在残余混杂。

要点

  • 整个队列严重感染发生率为每100患者年5.51例(95%CI 5.29至5.71)。
  • 与依那西普相比,托珠单抗严重感染风险更高(HR 1.22,95%CI 1.02至1.47)。
  • 培塞利珠单抗严重感染风险低于依那西普(HR 0.75,95%CI 0.58至0.97),但敏感性分析不再显著。

核心结论

  • 培塞利珠单抗的严重感染率在主要分析中低于依那西普,但在多项敏感性分析中不再显著,提示残余混杂可能解释所观察到的差异。
  • 作者认为不能据此得出培塞利珠单抗严重感染率低于其他生物制剂的结论,但其风险似乎并未如先前所提示的那样显著更高。

研究设计与样本

  • 英国风湿病学会类风湿关节炎生物制剂登记(BSRBR-RA)是一项前瞻性观察队列研究。
  • 本分析纳入新启用生物制剂的类风湿关节炎患者19282例,随访46771患者年。

主要发现

  • 主要结局严重感染定义为需住院、静脉抗生素治疗或导致死亡的感染事件。
  • 整个队列严重感染发生率为每100患者年5.51例(95%CI 5.29至5.71)。
  • 在完全校正模型中,与依那西普相比,托珠单抗严重感染风险更高(HR 1.22,95%CI 1.02至1.47),培塞利珠单抗风险更低(HR 0.75,95%CI 0.58至0.97)。
  • 严重感染后30天死亡率为10.4%(95%CI 9.2%至11.6%)。

关键数值与推荐

  • 严重感染定义为需住院、静脉抗生素治疗或导致死亡的感染事件。
  • 采用Cox比例风险模型校正潜在混杂因素后比较各生物制剂间的事件率。
  • 次要结局为按器官类别划分的感染率及感染后30天死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 培塞利珠单抗严重感染风险低于依那西普的结果在多项敏感性分析中不再显著,提示残余混杂可能解释所观察到的差异。
  • 作者认为不能据此得出培塞利珠单抗严重感染率低于其他生物制剂的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the incidence of serious infection (SI) across biologic drugs used to treat rheumatoid arthritis (RA) using data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). METHODS: The BSRBR-RA is a prospective observational cohort study. This analysis included patients with RA starting a new biologic. The primary outcome was SI defined as an infectious event requiring admission to hospital, intravenous antibiotics or resulting in death. Event rates were calculated and compared across biologics using Cox proportional hazards with adjustment for potential confounders. Secondary outcomes were the rate of infection by organ class and 30-day mortality following infection. RESULTS: This analysis included 19 282 patients with 46 771 years of follow-up. The incidence of SI was 5.51 cases per 100 patient years for the entire cohort (95% CI 5.29 to 5.71). Compared with etanercept, tocilizumab had a higher risk of SI (HR 1.22, 95% CI 1.02 to 1.47) and certolizumab pegol a lower risk of SI (HR 0.75, 95% CI 0.58 to 0.97) in the fully adjusted model. The 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). CONCLUSIONS: The rate of SI was lower with certolizumab pegol than etanercept in the primary analysis but the result was no longer significant in several sensitivity analyses performed suggesting residual confounding may account for the observed difference. From these results, it would be wrong to conclude that certolizumab pegol has a lower rate of SI than other biologics; however, the risk does not appear to be significantly higher as has previously been suggested.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018. PMID: 29592917. doi:10.1136/annrheumdis-2017-212825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。